The SeqOIA Cooperative Health Group Selects IntegraGen As the
Operator of Its Sequencing Platform as Part of the France Genomic
Medicine 2025 Plan

IntegraGen(Paris:ALINT)(FR0010908723 - ALINT), a
company specializing in the transformation of data from biological
samples into genomic information and diagnostic tools for oncology,
today announced that it has been selected by the Sequencing Omics
Information Analysis (SeqOIA) Cooperative Health Group (GCS) for the
operation of its high throughput sequencing platform. The SeqOIA GCS,
which includes the Assistance Publique- Hôpitaux de Paris, the Institut
Curie and the Gustave Roussy Cancer Center, communicated that it chose
IntegraGen’s proposal in response to a public tender it launched in
April 2018 to identify the operator of the Group’s platform dedicated to
the production of high-throughput sequencing data.

SeqOIA is the genomic platform within the Paris Region that was recently
selected by the French Ministry of Solidarity and Health for the
implementation of a pilot project aimed at providing and evaluating very
high-throughput sequencing platform within the France Genomic Medicine
2025 plan.

While awaiting the official notification of this decision, IntegraGen’s
team began utilizing its expertise and know-how to mobilize resources to
ensure a rapid set up and validation of the platform. The company
envisions this platform will enable the SeqOIA GCS to become a
world-wide leader in terms of high-throughput sequencing and the
associated innovative patient care which results from this project. The
platform will be established within the premises of the former Hospital
Broussais located in the 15th district of Paris. This will be
one of the two pilot platforms associated with the France Genomic
Medicine 2025 plan, which is under the leadership of AVIESAN with the
support of the French State. The objective of France Genomic Medicine
2025 is to position France as one of the world’s leading countries in
the field of genomic medicine.

IntegraGen noted that this contract will amount to €18 million over five
years and will provide the SeqOIA GCS access to DNA (exome and whole
genome) and RNA sequencing data from patients, primarily those suffering
from cancer and rare diseases.

Bernard Courtieu, CEO of IntegraGen stated: “We at IntegraGen
are extremely proud to join the SeqOIA group and to contribute to making
SeqOIA a world class reference for the field of Genomic Medicine as a
part of the framework of the France Genomic Medicine 2025 Plan. This is
not only a major step forward in terms of growth and profitability for
IntegraGen, it is also the acknowledgement of our know-how and expertise
in this field. I would like to especially thank all of IntegraGen’s
employees and partners who have built this tremendous amount of
expertise and whose hard work has been rewarded by the GCS.”

ABOUT INTEGRAGEN

IntegraGen is a company specializing in deciphering the human genome and
producing relevant and easily interpretable data for academic and
private laboratories. IntegraGen’s oncology efforts provide researchers
and clinicians with sophisticated tools for analysis and therapeutic
individualization of treatment approaches allowing them to tailor
therapy to the genetic profiles of patients. As of December 31, 2017,
IntegraGen had 40 employees and had generated revenue of €6.2 million in
2017. Based in Evry Genopole, IntegraGen also has an U.S. office in
Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN:
FR0010908723 - Ticker: ALINT - PEA-SME).